Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1Seizures 1Epilepsy 1Cognitive Dysfunction 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Anticonvulsants × Clear all
NCT03356769 2020-06-09

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

Peking Union Medical College Hospital

Phase 2 Unknown
98 enrolled

Epilepsy, Seizures, Tuberous Sclerosis, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡